Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389779 · ClinicalTrials.gov registry record · Phase 3
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 849
- Enrollment target
NCT00389779: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT00389779 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 849 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00389779, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 849 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic and diastolic hypertension despite treatment with full doses of three or more antihypertensive drugs, including a diuretic. Subjects will be randomized to darusentan (optimized dose), an active comparator, or placebo, administered orally. The treatment period for this trial is 14 weeks.
Interventions
- DRUG Guanfacine
- DRUG Darusentan
- DRUG Darusentan Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 849 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
What the finished NCT00389779 record still lists
NCT00389779 is an interventional study that assigns participants to a tested intervention. The registered 849 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 3 interventions - of which Guanfacine is the first listed.
NCT00389779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00389779 about?
NCT00389779 is a clinical study titled "DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension". This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to d...
What is the current status of trial NCT00389779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 849 participants. The study started on 2006-09. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00389779?
The interventions under investigation include: Guanfacine (DRUG), Darusentan (DRUG), Darusentan Placebo (DRUG).
Who is sponsoring clinical trial NCT00389779?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00389779's enrollment target sits among peer trials
849 389th of 2000 higher than 1,612 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06289673 · 850 participants · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia